Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company spun out of the University of Nottingham to develop and commercialise its proprietary EarlyCDT® liquid biopsy platform technology, noted today..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announced that it has entered into the licence agreement..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today provides an update on the business ahead of the..

Oncimmune Holdings plc (LON: ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced the appointment of Dr. Annalisa Jenkins, MBBS, FRCP to..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced that it has signed a framework agreement for an exclusive..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that the Company has validated its EarlyCDT®-Liver test on schedule..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology today announces it has appointed Bryan, Garnier & Co. and Berenberg as..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT®platform technology announced today that it has received confirmation from HMRC that the Ordinary Share..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces it has signed an exclusive agreement for distribution of its..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced that it has validated and launched a finger stick collection..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced its full year results for the year ended 31 May..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced it has signed an exclusive agreement for distribution of its..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced it has signed three new exclusive distribution agreements for its..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced that data relating to the development of its EarlyCDT®-Liver panel..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today provided the following update on the business ahead of the announcement..

Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, and Scancell Holdings plc, (‘Scancell’) the developer of novel immunotherapies for the..

Oncimmune Holdings PLC (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced the appointment of Shane Smith as Senior Vice President, Market..